Gerardo Hernandez Sells 920 Shares of TransMedics Group (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) CFO Gerardo Hernandez sold 920 shares of TransMedics Group stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $139.62, for a total value of $128,450.40. Following the completion of the transaction, the chief financial officer directly owned 15,064 shares in the company, valued at $2,103,235.68. This represents a 5.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

TransMedics Group Trading Down 1.5%

TMDX traded down $2.12 on Friday, reaching $136.51. 462,535 shares of the company’s stock were exchanged, compared to its average volume of 1,213,045. The company’s 50 day moving average is $124.55 and its 200-day moving average is $122.75. The company has a market cap of $4.66 billion, a price-to-earnings ratio of 55.27 and a beta of 2.06. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $156.00. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.29. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The firm had revenue of $143.82 million for the quarter, compared to analysts’ expectations of $145.33 million. During the same period in the previous year, the company posted $0.12 earnings per share. TransMedics Group’s revenue was up 32.2% compared to the same quarter last year. Equities analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Institutional Trading of TransMedics Group

Several large investors have recently modified their holdings of the business. Allworth Financial LP increased its position in shares of TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after acquiring an additional 113 shares during the last quarter. Investment Research Partners LLC acquired a new stake in TransMedics Group during the 3rd quarter valued at approximately $443,000. CIBC Bancorp USA Inc. acquired a new stake in TransMedics Group during the 3rd quarter valued at approximately $398,000. Kensington Investment Counsel LLC purchased a new stake in TransMedics Group during the 3rd quarter worth approximately $1,926,000. Finally, Advisory Services Network LLC acquired a new position in shares of TransMedics Group in the 3rd quarter valued at approximately $274,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TMDX has been the topic of several recent research reports. Jefferies Financial Group assumed coverage on shares of TransMedics Group in a report on Monday, October 13th. They set a “buy” rating and a $145.00 target price on the stock. Piper Sandler cut their price objective on TransMedics Group from $145.00 to $140.00 and set an “overweight” rating on the stock in a research report on Thursday, October 30th. Morgan Stanley boosted their price objective on TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Zacks Research downgraded TransMedics Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Finally, Needham & Company LLC reiterated a “buy” rating on shares of TransMedics Group in a report on Thursday, October 30th. Seven research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $133.00.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.